clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Parotid Diseases D010305 1 associated lipids
Achlorhydria D000126 1 associated lipids
Eye Infections D015817 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Morikawa K et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. 1996 Antimicrob. Agents Chemother. pmid:8726002
Arain TM et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. 1996 Antimicrob. Agents Chemother. pmid:8726034
Gibreel A et al. Contribution of the CmeABC efflux pump to macrolide and tetracycline resistance in Campylobacter jejuni. 2007 Antimicrob. Agents Chemother. pmid:17606685
la Porte CJ et al. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. 2009 Antimicrob. Agents Chemother. pmid:19015362
Hirschl AM et al. In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. 2000 Antimicrob. Agents Chemother. pmid:10858365
Goswami S et al. Anti-Helicobacter pylori potential of artemisinin and its derivatives. 2012 Antimicrob. Agents Chemother. pmid:22687518
Giacometti A et al. In vitro activity of aurein 1.2 alone and in combination with antibiotics against gram-positive nosocomial cocci. 2007 Antimicrob. Agents Chemother. pmid:17220421
Vermot D et al. Efficacy of clarithromycin versus that of clindamycin for single-dose prophylaxis of experimental streptococcal endocarditis. 1996 Antimicrob. Agents Chemother. pmid:8851620
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Cho SH et al. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. 2007 Antimicrob. Agents Chemother. pmid:17210775
Ji B et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. 2007 Antimicrob. Agents Chemother. pmid:17664316
Vaara M Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. 1993 Antimicrob. Agents Chemother. pmid:8383945
Gustavson LE et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. 1995 Antimicrob. Agents Chemother. pmid:8540719
Endo H et al. Effects of clarithromycin and amoxicillin on gastric emptying in rats. 2002 Antimicrob. Agents Chemother. pmid:12234874
Fernández-Roblas R et al. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10602744
Jung R et al. Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. 2000 Antimicrob. Agents Chemother. pmid:10681358
Hultén K et al. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. 1996 Antimicrob. Agents Chemother. pmid:9124830
Sassa K et al. Therapeutic effect of clarithromycin on a transplanted tumor in rats. 1999 Antimicrob. Agents Chemother. pmid:9869567
Chan GP et al. Clinical trial of clarithromycin for lepromatous leprosy. 1994 Antimicrob. Agents Chemother. pmid:8203847
Onyeji CO et al. Efficacies of liposome-encapsulated clarithromycin and ofloxacin against Mycobacterium avium-M. intracellulare complex in human macrophages. 1994 Antimicrob. Agents Chemother. pmid:8203849
Kamoda O et al. In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection. 2006 Antimicrob. Agents Chemother. pmid:16940102
Dean NC et al. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. 2006 Antimicrob. Agents Chemother. pmid:16569825
Bosnar M et al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. 2005 Antimicrob. Agents Chemother. pmid:15917536
Moon JE et al. Efficacy of macrolides and telithromycin against leptospirosis in a hamster model. 2006 Antimicrob. Agents Chemother. pmid:16723556
Tamaoki J et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. 1995 Antimicrob. Agents Chemother. pmid:7486901
Burton AJ et al. Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice. 2015 Antimicrob. Agents Chemother. pmid:25824218
Kohyama T et al. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. 1999 Antimicrob. Agents Chemother. pmid:10103198
Vance E et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. 1995 Antimicrob. Agents Chemother. pmid:7574530
Tsuda T et al. Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes. 2008 Antimicrob. Agents Chemother. pmid:18212111
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Debets-Ossenkopp YJ et al. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9756790
Hoppe JE and Bryskier A In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). 1998 Antimicrob. Agents Chemother. pmid:9559823
Dever LL et al. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. 1993 Antimicrob. Agents Chemother. pmid:8215288
Kashuba AD and Amsden GW Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. 1998 Antimicrob. Agents Chemother. pmid:9527816
Clark CL et al. Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies. 2007 Antimicrob. Agents Chemother. pmid:17876003
Liou JM et al. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. 2011 Antimicrob. Agents Chemother. pmid:21189342
Bae S et al. Antimicrobial resistance in Haemophilus influenzae respiratory tract isolates in Korea: results of a nationwide acute respiratory infections surveillance. 2010 Antimicrob. Agents Chemother. pmid:19884366
Kohno Y et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. 2007 Antimicrob. Agents Chemother. pmid:17709469
Lazard T et al. Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. 1993 Antimicrob. Agents Chemother. pmid:7684213
Emori M et al. Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. 1993 Antimicrob. Agents Chemother. pmid:7684214
Bohnert JA et al. Novel Piperazine Arylideneimidazolones Inhibit the AcrAB-TolC Pump in Escherichia coli and Simultaneously Act as Fluorescent Membrane Probes in a Combined Real-Time Influx and Efflux Assay. 2016 Antimicrob. Agents Chemother. pmid:26824939
Ji B et al. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. 1991 Antimicrob. Agents Chemother. pmid:1828136
Hardy RD et al. Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. 2003 Antimicrob. Agents Chemother. pmid:12709330
De R et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. 2009 Antimicrob. Agents Chemother. pmid:19204190
Tomioka H et al. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. 2002 Antimicrob. Agents Chemother. pmid:11796367
Miltner EC and Bermudez LE Mycobacterium avium grown in Acanthamoeba castellanii is protected from the effects of antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10858369
Kawai Y et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. 2013 Antimicrob. Agents Chemother. pmid:23459497
Nakamura S et al. Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice. 2010 Antimicrob. Agents Chemother. pmid:19949056
English ML et al. Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. 2012 Antimicrob. Agents Chemother. pmid:22290969
Jorgensen JH et al. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. 1991 Antimicrob. Agents Chemother. pmid:1834012
Fish DN and Abraham E Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. 1999 Antimicrob. Agents Chemother. pmid:10223952
Atkinson BA et al. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. 1995 Antimicrob. Agents Chemother. pmid:8619588
Greendyke R and Byrd TF Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. 2008 Antimicrob. Agents Chemother. pmid:18378709
Fernandez-Martin J et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. 1991 Antimicrob. Agents Chemother. pmid:1836943
Choi GE et al. Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense. 2012 Antimicrob. Agents Chemother. pmid:22564831
Jesus FP et al. In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. 2015 Antimicrob. Agents Chemother. pmid:26459895
Ferro BE et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. 2016 Antimicrob. Agents Chemother. pmid:26643335
Heifets LB et al. Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium. 1992 Antimicrob. Agents Chemother. pmid:1416852
Brown BA et al. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. 1992 Antimicrob. Agents Chemother. pmid:1416891
Biehle J and Cavalieri SJ In vitro susceptibility of Mycobacterium kansasii to clarithromycin. 1992 Antimicrob. Agents Chemother. pmid:1416897
Goldstein EJ et al. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans. 1998 Antimicrob. Agents Chemother. pmid:9593139
Chu SY et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. 1992 Antimicrob. Agents Chemother. pmid:1489187
Araujo FG et al. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1489188
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Gan VN et al. Pharmacokinetics of a clarithromycin suspension in infants and children. 1992 Antimicrob. Agents Chemother. pmid:1489191
Ji B et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. 1996 Antimicrob. Agents Chemother. pmid:8878595
Hafner R et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. 1998 Antimicrob. Agents Chemother. pmid:9517944
Fernandes PB et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. 1986 Antimicrob. Agents Chemother. pmid:2949695
Fattorini L et al. Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. 1998 Antimicrob. Agents Chemother. pmid:9517960
Falzari K et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. 2005 Antimicrob. Agents Chemother. pmid:15793125
Segreti J et al. In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2952061
Alhajlan M et al. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. 2013 Antimicrob. Agents Chemother. pmid:23545534
Benson CA et al. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms. 1987 Antimicrob. Agents Chemother. pmid:2952063
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Gelber RH et al. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. 1991 Antimicrob. Agents Chemother. pmid:1648889
Barry AL et al. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. 1987 Antimicrob. Agents Chemother. pmid:2952064
Sörberg M et al. Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. 1998 Antimicrob. Agents Chemother. pmid:9593154
Chin NX et al. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria. 1987 Antimicrob. Agents Chemother. pmid:2953303
Brophy DF et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. 2000 Antimicrob. Agents Chemother. pmid:10722500
Bowie WR et al. In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. 1987 Antimicrob. Agents Chemother. pmid:2953304
Lee JH et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. 2005 Antimicrob. Agents Chemother. pmid:15793150
Ji B et al. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. 1996 Antimicrob. Agents Chemother. pmid:8834886
Yamamoto T et al. Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. 1996 Antimicrob. Agents Chemother. pmid:8834892
Ji B et al. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? 1996 Antimicrob. Agents Chemother. pmid:8834894
Dattwyler RJ et al. Clarithromycin in treatment of early Lyme disease: a pilot study. 1996 Antimicrob. Agents Chemother. pmid:8834900
Versalovic J et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. 1996 Antimicrob. Agents Chemother. pmid:8834903
Yamazaki T et al. Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae. 2007 Antimicrob. Agents Chemother. pmid:17387152
Bogdanovich T et al. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. 2006 Antimicrob. Agents Chemother. pmid:16495248
Koh WJ et al. Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. 2013 Antimicrob. Agents Chemother. pmid:23183432
Berti AD et al. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. 2012 Antimicrob. Agents Chemother. pmid:22802248
Ji B et al. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. 1994 Antimicrob. Agents Chemother. pmid:7872741
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Skinner PS et al. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. 1994 Antimicrob. Agents Chemother. pmid:7872747
Zhanel GG and Karlowsky JA In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae. 2009 Antimicrob. Agents Chemother. pmid:19139284
Welsh L et al. In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8787907
Valero G et al. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. 1994 Antimicrob. Agents Chemother. pmid:7872769
Garey KW et al. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. 1999 Antimicrob. Agents Chemother. pmid:10223928
Fontana C et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. 2002 Antimicrob. Agents Chemother. pmid:12435674
Noreddin AM et al. Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. 2002 Antimicrob. Agents Chemother. pmid:12435719
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724